D-1104-2020 Class II Terminated

Recalled by Avet Pharmaceuticals, Inc. — East Brunswick, NJ

FDA drug recall D-1104-2020 was initiated by Avet Pharmaceuticals, Inc. on Mar 26, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level The recall status is terminated (terminated Mar 8, 2021). Affected quantity: a) 12,168; b) 17,196; c) 3,890.

Recall details

Product Type
Drugs
Report Date
Apr 15, 2020
Initiation Date
Mar 26, 2020
Termination Date
Mar 8, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 12,168; b) 17,196; c) 3,890

Product description

Losartan Potassium Tablets USP 100 mg, supplied in a) 30 count (NDC 23155-646-03, b) 90 count (NDC 23155-646-09) and 1000 count (NDC 23155-646-10) bottles, Rx only, Manufactured by: Vivimed Life Sciences Private Limited, Tamil Nadu, India Manufactured for: Heritage Pharmaceutical Inc., East Brunswick, NJ 08816

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level

Distribution pattern

Nationwide

Code information

a) CL018022B, exp Apr 2020 b) CL018010A Mar 2020; CL018017B, CL018018A exp Apr 2020 c) CL018011A, CL018012A exp Mar 2020; CL018013A, CL018015A, CL018016A, CL018017A, exp Apr 2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1104-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1104-2020. Report a data issue: hello@regdatalab.com.